KEI Staff's blog

Eleven of the 28 House democrats supporting Fast Track write USTR about Medicine IPR issues

Attached is a letter from eleven of the 28 House Democrats that supported the Trade Promotion Authority (TPA) Fast Track legislation, on the topic of intellectual property rights and medicine. The letter, which is moderate and cautious in substance, but overall helpful given where negotiations stand, closes by telling Ambassador Froman that "As members who support trade done right, we strongly believe that TPP must not inhibit access to lifesaving medicines."

Seminars on Drug Pricing: Part 2, Ruth Lopert

Ruth LopertOn Thursday, 23 July 2015, at 11AM Eastern Time (Washington, DC), KEI will host a seminar on drug pricing featuring Dr. Ruth Lopert, the Deputy Director of Pharmaceutical Policy and Strategy at the Center for Pharmaceutical Management, at Management Sciences for Health (MSH).

Duke letter to White House on the problems with the TPP IP Chapter

Attached below is a May 20, 2015 letter from Duke researchers to the White House Office of Science and Technology Policy, setting our problems in the TPP IP Chapter. The letter is signed by Jason Cross, the Director of the Innovation & Technology Policy Lab (ITPLab) at the Sanford School of Public Policy & Duke Law School, at Duke University.

The whole letter (available in PDF format here) is worth reading. Here are a few sections from the letter:


KEI TPP Briefing note 2015:1 Compulsory licenses on patents and the 3-step test

This is a briefing note prepared for TPP negotiators, addressing a single but important issue, the standards for issuing compulsory licenses in the TPP.

Letter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs.

Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary "to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease."

KEI Comments to DHHS on WHA Agenda 17.5 (Global Strategy and Plan of Action on Public Health, Innovation and IP)

Andy-IMG_3181_600x.pngOn Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here.

KEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding collection of economic data

Rajasingh-1-IMG_3157_1024x716.pngOn Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here:

Kassy Perry, speaking on behalf of ?, opposing AB 463, on transparency of drug R&D costs and subsidies

During the debate of California bill AB 463, on the Pharmaceutical Cost Transparency Act of 2015, Kassy Perry was using Twitter to attack the bill, posting links to and repeating pharmaceutical industry talking points. Who is Kassy Perry? A founder of Perry Communications, a Sacramento public relations and lobbying firm. This is her Twitter profile:

https://twitter.com/KassyPerry

Sony referred to "WIPO treaty for blind as "stalking horse" to "denigrate the rights of copyright owners"

In the new Wikileaks archives of leaked Sony documents (Link here), there is a memo (https://wikileaks.org/sony/docs/05/docs/DECE/DECE%20CP1%20-%20ss.doc.pdf), which describes Sony Pictures Entertainment (SPE) concern over the proposed WIPO treaty for copyright exceptions for persons who are blind or have other disabilities. The memo, undated in the Wikileaks archives, but probably written in 2009, included the following passages:

2014 Oct 3 version: Regional Comprehensive Economic Partnership, Japan IPR proposals, RCEP

(More KEI RCEP leaks here: http://keionline.org/rcep)

Attached is a leaked version of Japan's October 3, 2014 proposals for intellectual property for the Regional Comprehensive Economic Partnership.

Patents with government interests, by disease, 2010 to 2013

The attached PDF file provides counts on the number of patents with various search terms in the specification (spec/"search term"), and the number of those patents that declare either government rights in the patents (govt/government), an assignment to the US government (an/"united states of america"), or both. The complete counts are in the PDF file. The queries were done by Claire Cassedy on December 5, 2014.

Rajasingh on India-US dispute over patents on dasatinib, a drug to treat leukemia

link to video: https://www.youtube.com/watch?v=vU-JLDq02CE See also: http://keionline.org/node/2109.

Video script:

My name is Elizabeth Rajasingh.

I want to talk about a trade dispute between India and the United States, involving patents on a drug for leukemia.

Comments to USTR on the Out-of-Cycle Review for India due October 31, 2014.

michael_froman.png
Ambassador Michael Froman wants to block compulsory licenses on drug patents in India

KEI welcomes the Gilead HCV licenses, as a step to expand access to treatments. Notes challenges that remain

Today Gilead announced it will provide seven generic drug manufacturers licenses to make and sell two drugs that are used in combination to treat the Hepatitis C Virus (HCV) in 91 developing countries.

Syndicate content